8-K: XOMA Royalty Corp Reports Strong Q3 2024 Results Driven by New FDA Approval and Strategic Acquisition

XOMA Royalty Corporation announced its third quarter 2024 financial results, highlighted by the FDA approval of MIPLYFFA and a significant acquisition of early-stage assets from Twist Bioscience.

Summary

• XOMA Royalty Corporation reported its financial results for the third quarter of 2024, showing a significant increase in total income and revenues to $7.2 million, compared to $0.8 million in the same quarter of 2023.
• The company's cash receipts totaled $9.9 million for the quarter and $42.3 million for the first nine months of 2024.
• A key highlight was the FDA approval of Zevra Therapeutics' MIPLYFFA for Niemann-Pick disease type C, adding a sixth commercial asset to XOMA's portfolio.
• XOMA also acquired a 50% economic interest in Twist Bioscience's portfolio of over 60 early-stage assets for $15 million.
• Research and development expenses increased to $0.8 million due to costs associated with winding down an asset acquired in the Kinnate acquisition.
• General and administrative expenses rose to $8.0 million, primarily due to costs related to the Kinnate acquisition.
• A one-time, non-cash impairment charge of $14.0 million was recorded due to an evaluation of the Agenus Royalty Purchase Agreement.
• The company reported a net loss of $17.2 million for the quarter, primarily due to the impairment charge, compared to a net loss of $5.5 million in the same period last year.
• XOMA Royalty had cash and cash equivalents of $146.8 million as of September 30, 2024.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the significant revenue increase and strategic acquisitions, but it is tempered by the net loss and impairment charge. The company is making progress but faces some financial challenges.

Positives

• The FDA approval of MIPLYFFA significantly strengthens XOMA's commercial royalty portfolio.
• The acquisition of a 50% stake in Twist Bioscience's early-stage assets diversifies XOMA's portfolio and provides potential future revenue streams.
• The company's total income and revenues increased significantly year-over-year, demonstrating strong growth.
• XOMA's cash position remains strong at $146.8 million, providing financial flexibility.
• The company continues to build a portfolio of sustainable cashflow streams by selectively acquiring royalty economics across the lifecycle of drug development.

Negatives

• The company recorded a significant net loss of $17.2 million for the quarter, primarily due to a $14.0 million non-cash impairment charge.
• General and administrative expenses increased by $1.6 million, largely due to costs associated with the Kinnate acquisition.
• Research and development expenses increased due to the winding down of an asset acquired in the Kinnate acquisition.

Risks

• The company's financial results are subject to the success of its partners' drug development programs.
• The company's portfolio includes investigational compounds that may not receive regulatory approval.
• The company's future performance is dependent on the market viability of the products in which it has a royalty interest.
• The company's licensees may require substantial funds to continue development, which may not be available.
• The company's financial results are subject to the risk of impairment charges related to its royalty purchase agreements.

Future Outlook

The company anticipates potential commercial payments from various assets in its portfolio and is focused on the potential of its partnered programs and licensed technologies generating substantial milestone and royalty proceeds over time. The company also notes that Takeda will be hosting an R&D Day on December 12, 2024, where mezagitamab will be discussed.

Management Comments

• We continue to take a balanced approach to building a portfolio of sustainable cashflow streams by selectively acquiring royalty economics across the lifecycle of drug development, stated Owen Hughes, Chief Executive Officer of XOMA Royalty.
• The September approval of MIPLYFFA, the first therapy approved for patients living with Niemann-Pick disease Type C, adds to our growing commercial royalty portfolio, while the recent transaction with Twist Bioscience further expands our early-stage portfolio, a key focus for us as we look to distribute risk across a diversified portfolio.

Industry Context

This announcement reflects a trend in the biotech industry where companies are increasingly focusing on royalty monetization and strategic acquisitions to diversify their portfolios and secure future revenue streams. XOMA's approach of acquiring royalty rights across the drug development lifecycle is a common strategy to mitigate risk and generate sustainable cash flow.

Comparison to Industry Standards

• XOMA's royalty aggregation model is similar to companies like Royalty Pharma, which also acquires royalty interests in pharmaceutical products.
• The $15 million investment in Twist Bioscience's portfolio is a relatively small transaction compared to larger deals in the industry, but it provides access to a large number of early-stage assets.
• The increase in revenue from $0.8 million to $7.2 million year-over-year is a significant improvement, indicating the success of XOMA's strategy.
• The net loss of $17.2 million, primarily due to a one-time impairment charge, is not uncommon in the biotech industry, where companies often face volatility in their financial results due to the nature of drug development.

Stakeholder Impact

• Shareholders may be concerned about the net loss but encouraged by the revenue growth and strategic acquisitions.
• Employees may be impacted by the winding down of the Kinnate asset.
• Customers of XOMA's partners may benefit from the development of new therapies.
• Suppliers and creditors may be impacted by the company's financial performance.

Next Steps

• The company will continue to monitor the progress of its partnered programs and licensed technologies.
• XOMA will focus on the potential of its portfolio to generate substantial milestone and royalty proceeds.
• The company will participate in Takeda's R&D Day on December 12, 2024.

Key Dates

Keywords

royalty, biotechnology, pharmaceutical, MIPLYFFA, Twist Bioscience, FDA approval, acquisition, financial results, portfolio, commercial assets